Topline data from the SELECT trial look good. But this may not necessarily change payer coverage policies on weight loss agents, at least not in the short term.
Topline Data On Obesity Drug Wegovy’s Impact On Cardiovascular Outcomes Won’t Necessarily Change Payer Coverage Policies
